EP16.01. Optimizing Treatment Outcomes for L858R EGFR+ NSCLC - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Jo Monsen
Meta Tag
Speaker Jo Monsen
Topic Patient Advocacy
WCLC 2023 conference
patient rights
treatment outcomes
EGFR TKI Osimertinib
resistance to EGFR TKIs
alternative doses
drug concentration
pulsed Afatinib
EGFR mutations
clinical trial
Powered By